Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-69

And for clarity @Denial, I mean I am not a believer that they have anything that goes close to cover the cost of the P3 (ie:A$90m).

We know they have been previously offered a lowball that they rejected, so I know to the letter of the law, Mr Rennie, can always say there is "real interest".
That is what he has done all along, strung people along, by being vague and misleading.

He alluded to "hoping" this deal would cover the costs of the P3 and I would love to see that, as it gives this molecule a greater chance of making it to market, but I believe he has nothing like $90m and you guys will be asked to put your hand in your pocket again, upon FDA go ahead.

If he had A$90m in hand, both parties would have announced the below:
"We are pleased to announce that X big pharma company, has has agreed to fund the costs (up to $90m) of the upcoming P3 trial and receive exclusive distribution rights etc etc, CONDITIONAL on PAR receiving the greenlight from the FDA......
The share price would then double immediately (50c) and an additional cap raise could be done to cushion the cash account.

Just ask yourselves, why wouldn't both parties agree to the above? What is the downside of doing it this way??
Everyone wins. No big pharma has to stump up any cash if all goes wrong and PAR get to show to the world that they have a real backer that has put pen to paper.

Anyway, I have said it all before, as many have said, you will know soon!